-- MediSwitch Drug Interactions Import (Part 108/112)
INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26143, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26143, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26143, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26143, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26143, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27175, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27175, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27175, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27175, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27175, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27175, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27175, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27175, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27175, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27175, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27175, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27175, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27175, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27175, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27175, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27175, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27175, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27175, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27175, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27175, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27175, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27175, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27175, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27175, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27175, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27175, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27175, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27175, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27175, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27175, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27175, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27175, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27175, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27175, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27175, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27175, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27175, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23015, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(23015, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23015, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23015, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(23015, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23015, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(23015, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23015, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(23015, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(23015, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(23015, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(23015, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23015, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(23015, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(23015, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(23015, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(23015, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(23015, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(23015, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(23015, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(23015, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23015, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(23015, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23015, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(23015, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23015, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(23015, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23015, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(23015, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27137, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27137, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27137, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27137, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27137, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27137, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27137, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27137, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27137, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27137, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27137, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27137, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27137, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27137, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27137, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27137, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27137, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27137, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27137, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27137, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27137, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27137, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27137, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27137, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27137, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27137, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27137, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27137, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27137, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27137, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27137, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27137, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27137, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27137, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27137, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27137, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27137, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27164, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27164, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27164, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27164, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27164, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27164, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27164, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27164, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27164, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27164, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27164, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27164, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27164, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27164, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27164, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27164, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27164, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27164, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27164, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27164, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27164, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27164, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27164, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27164, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27164, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27164, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27164, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27164, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27164, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27164, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27164, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27164, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27164, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27164, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27164, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27164, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27164, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(20909, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(20909, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(20909, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(20909, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(20909, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(20909, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(20909, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(20909, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(20909, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(20909, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(20909, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(20909, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(20909, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(20909, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(20909, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(20909, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(20909, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(20909, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(20909, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(20909, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(20909, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(20909, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(20909, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(20909, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(20909, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(20909, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(20909, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(20909, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(20909, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(20909, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(20909, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(20909, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(20909, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(20909, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(20909, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(20909, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(20909, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26146, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26146, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26146, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26146, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26146, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26146, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26146, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26146, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26146, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26146, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26146, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26146, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26146, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26146, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26146, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26146, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26146, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26146, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26146, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26146, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26146, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26146, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26146, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26146, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26146, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26146, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26146, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26146, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26146, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26133, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26133, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26133, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26133, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26133, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26133, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26133, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26133, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26133, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26133, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26133, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26133, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26133, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26133, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26133, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26133, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26133, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26133, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26133, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26133, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26133, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26133, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26133, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26133, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26133, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26133, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26133, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26133, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26133, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26130, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26130, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26130, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26130, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26130, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26130, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26130, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26130, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26130, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26130, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26130, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26130, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26130, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26130, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26130, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26130, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26130, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26130, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26130, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26130, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26130, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26130, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26130, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26130, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26130, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26130, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26130, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26130, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26130, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27169, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27169, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27169, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27169, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27169, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27169, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27169, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27169, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27169, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27169, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27169, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27169, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27169, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27169, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27169, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27169, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27169, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27169, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27169, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27169, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27169, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27169, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27169, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27169, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27169, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27169, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27169, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27169, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27169, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27169, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27169, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27169, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27169, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27169, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27169, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27169, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27169, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(31036, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(31036, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(31036, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(31036, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(31036, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(31036, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(31036, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(31036, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(31036, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(31036, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(31036, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(31036, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(31036, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(31036, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(31036, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(31036, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(31036, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(31036, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(31036, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(31036, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(31036, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(31036, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(31036, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(31036, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(31036, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(31036, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(31036, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(31036, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(31036, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(31036, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(31036, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(31036, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(31036, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(31036, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(31036, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(31036, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(31036, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27148, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27148, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27148, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27148, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27148, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27148, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27148, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27148, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27148, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27148, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27148, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27148, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27148, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27148, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27148, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27148, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27148, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27148, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27148, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27148, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27148, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27148, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27148, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27148, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27148, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27148, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27148, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27148, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27148, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27148, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27148, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27148, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27148, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27148, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27148, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27148, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27148, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26120, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26120, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26120, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26120, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26120, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26120, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26120, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26120, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26120, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26120, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26120, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26120, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26120, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26120, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26120, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26120, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26120, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26120, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26120, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26120, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26120, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26120, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26120, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26120, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26120, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26120, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26120, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26120, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26120, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27176, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27176, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27176, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27176, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27176, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27176, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27176, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27176, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27176, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27176, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27176, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27176, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27176, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27176, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27176, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27176, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27176, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27176, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27176, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27176, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27176, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27176, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27176, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27176, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27176, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27176, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27176, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27176, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27176, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27176, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27176, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27176, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27176, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27176, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27176, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27176, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27176, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27147, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27147, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27147, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27147, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27147, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27147, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27147, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27147, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27147, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27147, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27147, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27147, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27147, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27147, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27147, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27147, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27147, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27147, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27147, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27147, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27147, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27147, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27147, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27147, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27147, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27147, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27147, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27147, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27147, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27147, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27147, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27147, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27147, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27147, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27147, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27147, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27147, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24166, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(24166, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(24166, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(24166, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24166, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24166, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(24166, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24166, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(24166, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(24166, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(24166, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24166, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(24166, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(24166, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24166, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(24166, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24166, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(24166, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24166, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(24166, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(24166, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(24166, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(24166, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(24166, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(24166, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(24166, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(24166, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24166, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24166, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(24166, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(24166, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24166, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(24166, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24166, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24166, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24166, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(24166, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27192, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27192, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27192, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27192, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27192, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27192, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27192, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27192, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27192, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27192, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27192, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27192, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27192, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27192, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27192, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27192, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27192, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27192, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27192, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27192, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27192, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27192, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27192, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27192, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27192, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27192, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27192, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27192, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27192, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27192, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27192, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27192, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27192, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27192, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27192, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27192, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27192, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24759, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(24759, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(24759, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(24759, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24759, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24759, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(24759, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24759, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(24759, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(24759, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(24759, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24759, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(24759, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(24759, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24759, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(24759, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24759, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(24759, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24759, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(24759, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(24759, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(24759, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(24759, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(24759, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(24759, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(24759, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(24759, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24759, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24759, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(24759, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(24759, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24759, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(24759, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24759, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24759, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24759, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(24759, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26132, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26132, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26132, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26132, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26132, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26132, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26132, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26132, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26132, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26132, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26132, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26132, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26132, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26132, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26132, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26132, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26132, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26132, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26132, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26132, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26132, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26132, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26132, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26132, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26132, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26132, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26132, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26132, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26132, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27201, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27201, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27201, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27201, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27201, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27201, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27201, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27201, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27201, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27201, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27201, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27201, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27201, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27201, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27201, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27201, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27201, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27201, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27201, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27201, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27201, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27201, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27201, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27201, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27201, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27201, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27201, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27201, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27201, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27201, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27201, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27201, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27201, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27201, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27201, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27201, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27201, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24161, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(24161, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(24161, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(24161, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24161, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24161, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(24161, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24161, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(24161, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(24161, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(24161, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24161, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(24161, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(24161, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24161, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(24161, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24161, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(24161, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24161, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(24161, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(24161, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(24161, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(24161, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(24161, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(24161, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(24161, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(24161, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24161, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24161, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(24161, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(24161, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24161, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(24161, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24161, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24161, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24161, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(24161, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26119, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26119, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26119, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26119, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26119, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26119, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26119, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26119, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26119, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26119, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26119, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26119, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26119, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26119, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26119, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26119, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26119, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26119, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26119, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26119, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26119, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26119, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26119, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26119, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26119, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26119, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26119, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26119, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26119, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24756, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(24756, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(24756, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(24756, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24756, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24756, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(24756, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24756, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(24756, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(24756, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(24756, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24756, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(24756, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(24756, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24756, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(24756, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24756, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(24756, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24756, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(24756, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(24756, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(24756, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(24756, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(24756, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(24756, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(24756, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(24756, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24756, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24756, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(24756, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(24756, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24756, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(24756, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24756, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24756, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24756, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(24756, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(9463, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(9463, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(9463, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(9463, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(9463, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(9463, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(9463, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(9463, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(9463, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(9463, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(9463, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(9463, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(9463, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(9463, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(9463, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(9463, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(9463, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(9463, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(9463, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(9463, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(9463, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(9463, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(9463, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(9463, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(9463, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(9463, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(9463, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(9463, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(9463, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(9463, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(9463, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(9463, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(9463, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(9463, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(9463, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(9463, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(9463, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27198, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27198, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27198, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27198, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27198, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27198, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27198, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27198, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27198, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27198, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27198, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27198, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27198, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27198, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27198, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27198, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27198, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27198, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27198, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27198, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27198, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27198, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27198, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27198, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27198, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27198, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27198, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27198, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27198, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27198, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27198, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27198, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27198, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27198, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27198, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27198, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27198, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17468, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(17468, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(17468, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(17468, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17468, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17468, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(17468, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17468, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(17468, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(17468, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(17468, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17468, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(17468, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(17468, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17468, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(17468, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17468, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(17468, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17468, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(17468, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(17468, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(17468, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(17468, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(17468, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17468, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(17468, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(17468, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17468, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17468, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(17468, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(17468, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17468, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(17468, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17468, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17468, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17468, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(17468, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(343, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(343, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(343, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(343, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(343, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(343, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(343, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(343, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(343, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(343, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(343, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(343, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(343, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(343, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(343, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(343, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(343, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(343, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(343, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(343, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(343, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(343, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(343, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(343, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(343, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(343, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(343, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(343, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(343, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(343, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(343, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(343, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(343, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(343, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(18060, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(18060, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(18060, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(18060, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(18060, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(18060, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(18060, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(18060, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(18060, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(18060, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(18060, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(18060, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(18060, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(18060, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(18060, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(18060, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(18060, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(18060, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(18060, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(18060, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(18060, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(18060, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(18060, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(18060, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(18060, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(18060, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(18060, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(18060, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(18060, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(18060, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(18060, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(18060, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(18060, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(18060, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(18060, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(18060, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(18060, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(29017, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(29017, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(29017, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(29017, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(29017, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(29017, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(29017, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(29017, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(29017, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(29017, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(29017, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(29017, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(29017, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(29017, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(29017, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(29017, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(29017, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(29017, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(29017, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(29017, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(29017, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(29017, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(29017, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(29017, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(29017, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(29017, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(29017, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(29017, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(29017, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(29017, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(29017, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(29017, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(29017, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(29017, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(29017, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(29017, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(29017, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27205, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27205, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27205, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27205, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27205, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27205, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27205, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27205, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27205, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27205, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27205, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27205, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27205, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27205, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27205, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27205, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27205, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27205, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27205, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27205, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27205, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27205, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27205, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27205, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27205, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27205, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27205, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27205, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27205, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27205, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27205, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27205, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27205, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27205, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27205, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27205, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27205, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27874, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Live attenuated influenza vaccine (LAIV), intranasal: Avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate use, unless medically indicated. (7) 7.1 Influenza Vaccines Live Attenuated Influenza Vaccine The concurrent use of oseltamivir phosphate with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for oseltamivir phosphate to inhibit replication of live vaccine virus and possibly reduce the efficacy of LAIV, avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate administration, unless medically indicated. Inactivated Influenza Vaccine Inactivated influenza vaccine can be administered at any time relative to use of oseltamivir phosphate. ', 'DailyMed'),
(11147, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Live attenuated influenza vaccine (LAIV), intranasal: Avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate use, unless medically indicated. (7) 7.1 Influenza Vaccines Live Attenuated Influenza Vaccine The concurrent use of oseltamivir phosphate with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for oseltamivir phosphate to inhibit replication of live vaccine virus and possibly reduce the efficacy of LAIV, avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate administration, unless medically indicated. Inactivated Influenza Vaccine Inactivated influenza vaccine can be administered at any time relative to use of oseltamivir phosphate. ', 'DailyMed'),
(27876, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Live attenuated influenza vaccine (LAIV), intranasal: Avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate use, unless medically indicated. (7) 7.1 Influenza Vaccines Live Attenuated Influenza Vaccine The concurrent use of oseltamivir phosphate with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for oseltamivir phosphate to inhibit replication of live vaccine virus and possibly reduce the efficacy of LAIV, avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate administration, unless medically indicated. Inactivated Influenza Vaccine Inactivated influenza vaccine can be administered at any time relative to use of oseltamivir phosphate. ', 'DailyMed'),
(27873, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Live attenuated influenza vaccine (LAIV), intranasal: Avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate use, unless medically indicated. (7) 7.1 Influenza Vaccines Live Attenuated Influenza Vaccine The concurrent use of oseltamivir phosphate with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for oseltamivir phosphate to inhibit replication of live vaccine virus and possibly reduce the efficacy of LAIV, avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate administration, unless medically indicated. Inactivated Influenza Vaccine Inactivated influenza vaccine can be administered at any time relative to use of oseltamivir phosphate. ', 'DailyMed'),
(27872, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Live attenuated influenza vaccine (LAIV), intranasal: Avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate use, unless medically indicated. (7) 7.1 Influenza Vaccines Live Attenuated Influenza Vaccine The concurrent use of oseltamivir phosphate with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for oseltamivir phosphate to inhibit replication of live vaccine virus and possibly reduce the efficacy of LAIV, avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate administration, unless medically indicated. Inactivated Influenza Vaccine Inactivated influenza vaccine can be administered at any time relative to use of oseltamivir phosphate. ', 'DailyMed'),
(18433, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Live attenuated influenza vaccine (LAIV), intranasal: Avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate use, unless medically indicated. (7) 7.1 Influenza Vaccines Live Attenuated Influenza Vaccine The concurrent use of oseltamivir phosphate with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for oseltamivir phosphate to inhibit replication of live vaccine virus and possibly reduce the efficacy of LAIV, avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate administration, unless medically indicated. Inactivated Influenza Vaccine Inactivated influenza vaccine can be administered at any time relative to use of oseltamivir phosphate. ', 'DailyMed'),
(24309, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Live attenuated influenza vaccine (LAIV), intranasal: Avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate use, unless medically indicated. (7) 7.1 Influenza Vaccines Live Attenuated Influenza Vaccine The concurrent use of oseltamivir phosphate with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for oseltamivir phosphate to inhibit replication of live vaccine virus and possibly reduce the efficacy of LAIV, avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate administration, unless medically indicated. Inactivated Influenza Vaccine Inactivated influenza vaccine can be administered at any time relative to use of oseltamivir phosphate. ', 'DailyMed'),
(27877, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Live attenuated influenza vaccine (LAIV), intranasal: Avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate use, unless medically indicated. (7) 7.1 Influenza Vaccines Live Attenuated Influenza Vaccine The concurrent use of oseltamivir phosphate with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for oseltamivir phosphate to inhibit replication of live vaccine virus and possibly reduce the efficacy of LAIV, avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate administration, unless medically indicated. Inactivated Influenza Vaccine Inactivated influenza vaccine can be administered at any time relative to use of oseltamivir phosphate. ', 'DailyMed'),
(1606, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(27297, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(23735, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(2973, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(1595, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(15795, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(1598, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(23733, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(11893, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(1609, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(2975, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(16716, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(1793, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(15335, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(23595, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(19499, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(15347, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(15339, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(27298, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(20779, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(15341, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(2019, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(28719, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(23732, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(18125, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(23734, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(22585, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(15340, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(1593, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(25695, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(2977, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(1607, 'drug_class', 'N/A', 'severe', 'Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that BISOPROLOL FUMARATE be discontinued for several days before the withdrawal of clonidine. BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, su', 'DailyMed'),
(25471, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(25471, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(25471, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(25471, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(19230, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19230, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(19230, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(19230, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13870, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(13870, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13870, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(13870, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(31734, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(31734, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(31734, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(31734, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23949, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(23949, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23949, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(23949, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(5026, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(5026, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(5026, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(5026, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13042, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(13042, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13042, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(13042, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(17273, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(17273, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(17273, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(17273, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(25454, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(25454, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(25454, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(25454, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(31147, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(31147, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(31147, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(31147, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(18156, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(18156, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(18156, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(18156, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(24885, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(24885, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(24885, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(24885, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(24886, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(24886, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(24886, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(24886, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(4861, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(4861, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(4861, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(4861, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(19229, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19229, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(19229, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(19229, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(25628, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(25628, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(25628, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(25628, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(19231, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19231, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(19231, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(19231, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(9138, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(9138, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(9138, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(9138, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(19154, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19154, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(19154, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(19154, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(31146, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(31146, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(31146, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(31146, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13043, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(13043, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13043, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(13043, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(3433, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(3433, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(3433, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(3433, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(19237, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19237, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(19237, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(19237, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(24087, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(24087, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(24087, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(24087, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(17971, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(17971, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(17971, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(17971, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(19235, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19235, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(19235, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(19235, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(24887, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(24887, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(24887, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(24887, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(5029, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(5029, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(5029, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(5029, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(19228, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19228, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(19228, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(19228, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(5039, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(5039, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(5039, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(5039, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(25625, 'olanzapine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(25625, 'tramadol', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(25625, 'drug_class', 'N/A', 'contraindicated', '7.1 Monoamine Oxidase Inhibitors (MAOI) There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long elim', 'DailyMed'),
(25625, 'iron', 'N/A', 'minor', '7.3 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(25471, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(25471, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(25471, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(25471, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25471, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(25471, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(25471, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25471, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(25471, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25471, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(25471, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25471, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(25471, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(25471, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(25471, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25471, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(25471, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25471, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(25471, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(25471, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(25471, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(25471, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(25471, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25471, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(25222, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(25222, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(25222, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(25222, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(25222, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25222, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(25222, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(25222, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25222, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(25222, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25222, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(25222, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25222, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(25222, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(25222, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25222, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(25222, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25222, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(25222, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(25222, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(25222, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(25222, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(25222, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25222, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(23999, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(23999, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(23999, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(23999, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(23999, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(23999, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(23999, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(23999, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(23999, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(23999, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(23999, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(23999, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(23999, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(23999, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(23999, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(23999, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(23999, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(23999, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(23999, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(23999, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(23999, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(23999, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(23999, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23999, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(30057, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(30057, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(30057, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(30057, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(30057, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30057, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(30057, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(30057, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30057, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(30057, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30057, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(30057, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30057, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(30057, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(30057, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30057, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(30057, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30057, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(30057, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(30057, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(30057, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(30057, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(30057, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30057, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(20891, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(20891, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(20891, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(20891, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(20891, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(20891, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(20891, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(20891, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(20891, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(20891, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(20891, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(20891, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(20891, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(20891, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(20891, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(20891, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(20891, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(20891, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(20891, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(20891, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(20891, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(20891, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(20891, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20891, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(19230, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(19230, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(19230, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19230, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19230, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(19230, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(19230, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19230, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19230, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19230, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(19230, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19230, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(19230, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(19230, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19230, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(19230, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19230, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(19230, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(19230, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(19230, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(19230, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19230, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(19230, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19230, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(12959, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(12959, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(12959, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(12959, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(12959, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(12959, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(12959, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(12959, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(12959, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(12959, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(12959, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(12959, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(12959, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(12959, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(12959, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(12959, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(12959, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(12959, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(12959, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(12959, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(12959, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(12959, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(12959, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12959, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(32302, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(32302, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(32302, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(32302, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(32302, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(32302, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(32302, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(32302, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(32302, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(32302, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(32302, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(32302, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(32302, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(32302, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(32302, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(32302, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(32302, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(32302, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(32302, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(32302, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(32302, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(32302, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(32302, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32302, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(21605, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(21605, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(21605, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(21605, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(21605, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(21605, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(21605, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(21605, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(21605, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(21605, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(21605, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(21605, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(21605, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(21605, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(21605, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(21605, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(21605, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(21605, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(21605, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(21605, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(21605, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(21605, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(21605, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(21605, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(10592, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(10592, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(10592, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(10592, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(10592, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(10592, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(10592, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(10592, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(10592, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(10592, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(10592, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(10592, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(10592, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(10592, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(10592, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(10592, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(10592, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(10592, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(10592, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(10592, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(10592, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(10592, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(10592, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(10592, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(18830, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(18830, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(18830, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(18830, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(18830, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(18830, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(18830, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(18830, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(18830, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(18830, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(18830, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(18830, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(18830, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(18830, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(18830, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(18830, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(18830, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(18830, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(18830, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(18830, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(18830, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(18830, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(18830, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(18830, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(31734, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(31734, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(31734, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(31734, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(31734, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(31734, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(31734, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(31734, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(31734, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(31734, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(31734, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(31734, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(31734, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(31734, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(31734, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(31734, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(31734, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(31734, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(31734, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(31734, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(31734, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(31734, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(31734, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31734, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(23949, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(23949, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(23949, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(23949, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(23949, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(23949, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(23949, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(23949, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(23949, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(23949, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(23949, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(23949, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(23949, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(23949, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(23949, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(23949, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(23949, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(23949, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(23949, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(23949, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(23949, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(23949, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23949, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(24000, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(24000, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(24000, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(24000, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(24000, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(24000, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(24000, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(24000, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(24000, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(24000, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(24000, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(24000, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(24000, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(24000, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(24000, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(24000, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(24000, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(24000, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(24000, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(24000, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(24000, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(24000, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(24000, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24000, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(13042, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(13042, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(13042, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(13042, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(13042, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(13042, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(13042, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(13042, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(13042, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(13042, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(13042, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(13042, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(13042, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(13042, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(13042, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(13042, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(13042, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(13042, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(13042, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(13042, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(13042, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(13042, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13042, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(19808, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(19808, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(19808, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(19808, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19808, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19808, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(19808, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(19808, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19808, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19808, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19808, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(19808, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19808, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(19808, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(19808, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19808, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(19808, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19808, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(19808, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(19808, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(19808, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(19808, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19808, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19808, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(19774, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(19774, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(19774, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(19774, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19774, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19774, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(19774, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(19774, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19774, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19774, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19774, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(19774, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19774, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(19774, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(19774, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19774, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(19774, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19774, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(19774, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(19774, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(19774, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(19774, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19774, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19774, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(31147, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(31147, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(31147, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(31147, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(31147, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(31147, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(31147, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(31147, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(31147, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(31147, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(31147, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(31147, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(31147, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(31147, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(31147, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(31147, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(31147, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(31147, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(31147, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(31147, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(31147, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(31147, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31147, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(13619, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(13619, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(13619, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(13619, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(13619, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(13619, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(13619, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(13619, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(13619, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(13619, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(13619, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(13619, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(13619, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(13619, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(13619, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(13619, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(13619, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(13619, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(13619, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(13619, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(13619, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(13619, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(13619, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13619, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(4370, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(4370, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(4370, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(4370, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(4370, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(4370, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(4370, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(4370, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(4370, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(4370, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(4370, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(4370, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(4370, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(4370, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(4370, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(4370, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(4370, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(4370, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(4370, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(4370, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(4370, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(4370, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(4370, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(4370, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(4370, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(14176, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(14176, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(14176, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(14176, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(14176, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(14176, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(14176, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(14176, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(14176, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(14176, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(14176, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(14176, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(14176, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(14176, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(14176, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(14176, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(14176, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(14176, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(14176, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(14176, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(14176, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(14176, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(14176, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(14176, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(30056, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(30056, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(30056, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(30056, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(30056, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30056, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(30056, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(30056, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30056, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(30056, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30056, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(30056, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30056, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(30056, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(30056, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30056, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(30056, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30056, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(30056, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(30056, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(30056, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(30056, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(30056, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30056, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(26606, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(26606, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(26606, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(26606, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(26606, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(26606, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(26606, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(26606, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(26606, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26606, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(26606, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(26606, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(26606, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(26606, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(26606, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(26606, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(26606, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(26606, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(26606, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(26606, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(26606, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(26606, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(26606, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26606, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(12960, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(12960, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(12960, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(12960, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(12960, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(12960, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(12960, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(12960, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(12960, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(12960, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(12960, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(12960, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(12960, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(12960, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(12960, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(12960, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(12960, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(12960, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(12960, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(12960, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(12960, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(12960, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(12960, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12960, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(19229, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(19229, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(19229, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19229, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19229, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(19229, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(19229, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19229, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19229, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19229, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(19229, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19229, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(19229, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(19229, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19229, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(19229, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19229, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(19229, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(19229, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(19229, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(19229, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19229, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19229, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(19229, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(16782, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(16782, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(16782, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(16782, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(16782, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(16782, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(16782, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(16782, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(16782, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(16782, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(16782, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(16782, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(16782, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(16782, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(16782, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(16782, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(16782, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(16782, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(16782, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(16782, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(16782, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(16782, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(16782, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(16782, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(52, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(52, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(52, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(52, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(52, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(52, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(52, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(52, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(52, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(52, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(52, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(52, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(52, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(52, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(52, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(52, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(52, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(52, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(52, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(52, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(52, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(52, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(52, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(52, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(3412, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(3412, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(3412, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(3412, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(3412, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(3412, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(3412, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(3412, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(3412, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(3412, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(3412, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(3412, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(3412, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(3412, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(3412, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(3412, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(3412, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(3412, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(3412, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(3412, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(3412, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(3412, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(3412, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3412, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(25628, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(25628, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(25628, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(25628, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25628, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(25628, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(25628, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25628, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(25628, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25628, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(25628, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25628, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(25628, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(25628, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25628, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(25628, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25628, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(25628, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(25628, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(25628, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(25628, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(25628, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25628, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(12958, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(12958, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(12958, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(12958, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(12958, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(12958, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(12958, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(12958, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(12958, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(12958, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(12958, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(12958, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(12958, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(12958, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(12958, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(12958, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(12958, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(12958, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(12958, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(12958, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(12958, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(12958, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(12958, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(12958, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(7103, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(7103, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(7103, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(7103, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(7103, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(7103, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(7103, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(7103, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(7103, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(7103, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(7103, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(7103, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(7103, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(7103, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(7103, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(7103, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(7103, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(7103, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(7103, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(7103, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(7103, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(7103, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(7103, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(7103, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(32301, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(32301, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(32301, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(32301, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(32301, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(32301, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(32301, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(32301, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(32301, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(32301, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(32301, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(32301, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(32301, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(32301, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(32301, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(32301, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(32301, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(32301, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(32301, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(32301, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(32301, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(32301, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(32301, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32301, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(30190, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(30190, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(30190, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(30190, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(30190, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30190, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(30190, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(30190, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30190, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(30190, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30190, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(30190, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30190, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(30190, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(30190, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30190, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(30190, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30190, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(30190, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(30190, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(30190, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(30190, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(30190, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30190, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(26605, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(26605, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(26605, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(26605, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26605, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(26605, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(26605, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(26605, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(26605, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(26605, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(26605, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(26605, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(26605, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(26605, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(26605, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(26605, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(26605, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(26605, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(26605, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(26605, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(26605, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(26605, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(26605, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26605, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(19231, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(19231, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(19231, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19231, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19231, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(19231, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(19231, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19231, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19231, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19231, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(19231, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19231, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(19231, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(19231, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19231, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(19231, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19231, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(19231, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(19231, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(19231, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(19231, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19231, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19231, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(20892, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(20892, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(20892, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(20892, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(20892, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(20892, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(20892, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(20892, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(20892, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(20892, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(20892, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(20892, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(20892, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(20892, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(20892, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(20892, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(20892, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(20892, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(20892, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(20892, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(20892, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(20892, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(20892, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(20892, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(31146, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(31146, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(31146, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(31146, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(31146, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(31146, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(31146, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(31146, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(31146, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(31146, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(31146, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(31146, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(31146, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(31146, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(31146, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(31146, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(31146, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(31146, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(31146, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(31146, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(31146, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(31146, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(31146, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(13043, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(13043, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(13043, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(13043, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(13043, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(13043, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(13043, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(13043, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(13043, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(13043, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(13043, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(13043, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(13043, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(13043, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(13043, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(13043, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(13043, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(13043, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(13043, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(13043, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(13043, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(13043, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(13043, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(23998, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(23998, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(23998, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(23998, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(23998, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(23998, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(23998, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(23998, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(23998, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(23998, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(23998, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(23998, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(23998, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(23998, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(23998, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(23998, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(23998, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(23998, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(23998, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(23998, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(23998, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(23998, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(23998, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(23998, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(32234, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(32234, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(32234, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(32234, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(32234, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(32234, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(32234, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(32234, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(32234, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(32234, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(32234, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(32234, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(32234, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(32234, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(32234, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(32234, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(32234, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(32234, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(32234, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(32234, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(32234, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(32234, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(32234, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(32234, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(30059, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(30059, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(30059, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(30059, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(30059, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30059, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(30059, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(30059, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30059, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(30059, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30059, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(30059, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30059, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(30059, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(30059, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30059, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(30059, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30059, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(30059, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(30059, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(30059, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(30059, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(30059, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30059, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(9189, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(9189, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(9189, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(9189, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(9189, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(9189, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(9189, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(9189, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(9189, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(9189, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(9189, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(9189, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(9189, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(9189, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(9189, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(9189, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(9189, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(9189, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(9189, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(9189, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(9189, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(9189, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(9189, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9189, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(24002, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(24002, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(24002, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(24002, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(24002, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(24002, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(24002, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(24002, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(24002, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(24002, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(24002, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(24002, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(24002, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(24002, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(24002, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(24002, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(24002, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(24002, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(24002, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(24002, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(24002, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(24002, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(24002, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(24002, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(26604, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(26604, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(26604, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(26604, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(26604, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(26604, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(26604, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(26604, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(26604, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(26604, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(26604, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(26604, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(26604, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(26604, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(26604, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(26604, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(26604, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(26604, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(26604, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(26604, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(26604, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(26604, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(26604, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26604, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(19228, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(19228, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(19228, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(19228, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19228, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(19228, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(19228, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19228, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19228, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19228, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(19228, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19228, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(19228, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(19228, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(19228, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(19228, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(19228, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(19228, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(19228, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(19228, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(19228, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(19228, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19228, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(15293, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(15293, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(15293, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(15293, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(15293, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(15293, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(15293, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(15293, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(15293, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(15293, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(15293, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(15293, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(15293, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(15293, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(15293, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(15293, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(15293, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(15293, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(15293, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(15293, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(15293, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(15293, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(15293, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(15293, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(25625, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(25625, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(25625, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(25625, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25625, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(25625, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(25625, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25625, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(25625, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25625, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(25625, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25625, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(25625, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(25625, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(25625, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(25625, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(25625, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(25625, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(25625, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(25625, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(25625, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(25625, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25625, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(30191, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(30191, 'insulin human', 'N/A', 'moderate', 'Drug Interactions A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in hyperglycemia: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibito', 'DailyMed'),
(30191, 'olanzapine', 'N/A', 'minor', '7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)]. Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.', 'DailyMed'),
(30191, 'fluoxetine', 'N/A', 'contraindicated', 'Do not use thioridazine within 5 weeks of discontinuing fluoxetine (4, 7.9) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.9) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (7.9) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (7.9) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.9) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.9) Serotonergic Drugs: Potential for Serotonin Synd', 'DailyMed'),
(30191, 'fluoxetine hydrochloride', 'N/A', 'minor', 'Olanzapine – Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30191, 'fluoxetine capsules', 'N/A', 'minor', 'NSAIDs, Aspirin, Warfarin):May potentiate the risk of bleeding (7.6) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.8, 7.9) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules (7.9) 7.1. Olanzapine - Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for olanzapine and fluoxetine hydrochloride capsules.', 'DailyMed'),
(30191, 'eszopiclone', 'N/A', 'minor', 'When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.', 'DailyMed'),
(30191, 'fluoxetine hydrochloride, choline', 'N/A', 'minor', 'Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30191, 'glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(30191, 'divalproex sodium', 'N/A', 'major', 'Drugs for which a potentially important valproate interaction has been observed Amitriptyline/Nortriptyline Carbamazepine/carbamazepine-10,11-Epoxide Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Phenytoin Tolbutamide in vitro Warfarin in vitro Zidovudine Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Clozapine Lithium Lorazepam Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30191, 'prasterone and ibuprofen', 'N/A', 'minor', 'Prasterone may theoretically interact with one or more of the following drugs: carbamazepine, phenothiazines (e.g., acetophenazine, chlorpromazine, chlorprothixene, ethopropazine, fluphenazine, mesordiazine, methdilazine, perazine, perphenazine, pipotiazine, prochlorperazine, promazine, promethazine, propiomazine, thioridazine, trifluoperazine, triflupromazine), citalopram; escitalopram; clozapine, conjugated estrogens; estherified estrogens; estradiol; estradiol cypionate; estropipate; ethinyl estradiol, fluoxetine, fluvoxamine; haloperidol, lithium, loxapine, molindone, olanzapine, paroxetine, quetiapine, risperodone, sertraline, testosterone, triazolam and valproic acid.', 'DailyMed'),
(30191, 'valproic acid', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30191, 'repaglinide', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'tetrabenazine', 'N/A', 'moderate', '7.6Neuroleptic Drugs The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of tetrabenazine and dopamine antagonists or antipsychotics (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) [see Warnings and Precautions (5.4, 5.5, 5.6)].', 'DailyMed'),
(30191, 'glipizide', 'N/A', 'minor', 'The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs.', 'DailyMed'),
(30191, 'insulin degludec', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'insulin glargine', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of LANTUS Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'insulin aspart', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'insulin detemir', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'insulin glargine-aglr', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of REZVOGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'insulin aspart injection', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'valproate sodium', 'N/A', 'minor', 'Olanzapine No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.', 'DailyMed'),
(30191, 'olanzapine and fluoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine capsules in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine capsules. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine capsules or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine capsules and other CNS-active drugs is required (7.2) Anti', 'DailyMed'),
(30191, 'insulin lispro', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of HUMALOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'fluoxetine hcl', 'N/A', 'minor', 'Olanzapine—Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.', 'DailyMed'),
(30191, 'insulin lispro-aabc', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'olanzapine and fuoxetine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS The risks of using olanzapine and fluoxetine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with olanzapine and fluoxetine or when olanzapine and fluoxetine capsules have been recently discontinued (5.6, 7.7) CN S Acting Drugs: Caution is advised if the concomitant administration of olanzapine and fluoxetine and other CNS-active drugs is required (7.2) A n t ihypertensive Agent: Enhanced ant', 'DailyMed'),
(30191, 'olanzapine pamoate', 'N/A', 'minor', '(7.1) Carbamazepine: Increased clearance of olanzapine. (7.1) Fluvoxamine: May increase olanzapine levels. (7.1) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions (7.2)].', 'DailyMed'),
(30191, 'olanzapine and fluoxetine hydrochloride', 'N/A', 'contraindicated', 'The drug-drug interactions sections of fluoxetine and olanzapine are applicable to SYMBYAX. Monoamine Oxidase Inhibitor (MAOI): (2.4, 2.5, 4.1, 5.6, 7.1) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with SYMBYAX or when SYMBYAX has been recently discontinued (5.6, 7.7) CNS Acting Drugs: Caution is advised if the concomitant administration of SYMBYAX and other CNS-active drugs is required (7.2) Antihypertensive Agent: Enhanced antihypertensive effect (7.7) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists (7.7) Benzodiazepines: May potentiate orthostatic hypotension and sedation (7.6, 7.7) Clozapine: May elevate clozapine levels (7.7) Haloperid', 'DailyMed'),
(30191, 'selegiline', 'N/A', 'minor', 'No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.', 'DailyMed'),
(30191, 'pioglitazone and glimepiride', 'N/A', 'minor', 'The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.', 'DailyMed'),
(30191, 'insulin glargine-yfgn', 'N/A', 'minor', 'Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'insulin degludec and liraglutide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'insulin glargine and lixisenatide', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of SOLIQUA 100/33 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'insulin aspart-xjhz', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of KIRSTY Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'insulin aspart-szjj', 'N/A', 'minor', 'Drugs That May Decrease the Blood Glucose Lowering Effect of MERILOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(30191, 'olanzapine and samidorphan l-malate', 'N/A', 'minor', '(7.1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7.1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan [see Clinical Pharmacology (12.3)], which may reduce LYBALVI efficacy.', 'DailyMed'),
(29195, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(28357, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(9310, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(20758, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(4825, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(28356, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(10632, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(20759, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(27249, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(13016, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(27214, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(4995, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(2944, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(10634, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(23244, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(29196, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(28824, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(27094, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(28823, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(23243, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(10633, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(13015, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(27250, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Inhibitors of CYP3A4 may increase the concentration of VESIcare. (7.1) Inducers of CYP3A4 may decrease the concentration of VESIcare. (7.2) 7.1 Potent CYP3A4 Inhibitors Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean Cmax and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The effects of weak or moderate CYP3A4 inhibitors were not examined. 7.2 CYP3A4 Inducers There were no in vivo studies conducted to evaluate the effect of CYP3A4 inducers', 'DailyMed'),
(31533, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(28843, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(4751, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(28794, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30137, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(12664, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27486, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(17824, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(20026, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(28844, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(17825, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30614, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(29715, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(11962, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(28793, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(727, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(4752, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(29714, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(18892, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32311, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(20027, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30613, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27485, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(12665, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(29713, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(7996, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(18890, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(18099, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27484, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19827, 'hydrochlorothiazide', 'N/A', 'major', '7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(5357, 'iron', 'N/A', 'major', '[See Clinical Pharmacology (12.5)] It is theoretically possible that lansoprazole and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).', 'DailyMed');

